AeroPace System
Lungpacer Medical USA, Inc. · Decision date Dec 4, 2024
What did the FDA approve?
FDA records P240012 as an original PMA application. The recorded decision is approval, dated Dec 4, 2024.
FDA approval order statement
Approval for AeroPace System. The AeroPace System is indicated to improve weaning success increase weaning, reduce ventilator days, and reduce reintubation - in patients ages 18 years or older on mechanical ventilation >= 96 hours and who have not weaned.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Anesthesiology
- Decision date
- Dec 4, 2024
Regulatory record facts
- Identifier
- P240012
- Regulatory pathway
- Premarket approval application
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- Decision code
- APPR
- Decision date
- Dec 4, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transvenous temporary phrenic nerve stimulator.
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240012 received
Application receipt date recorded by FDA.
P240012 · FDA decision
APPR
P240012/S008 · Related supplement
AeroPace System
Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AeroPace SystemP240012/S008 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 25, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lungpacer Medical USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 260 Sierra Dr., Suite 116, Exton, PA, 19341
Sources and methodology
- Original FDA record: P240012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records